Post-Conference Perspectives: Updates in HER2+ Metastatic Colorectal Cancer (mCRC); ASCO 2023 Highlights

home / news-network / post-conference-perspectives-updates-in-her2-metastatic-colorectal-cancer-asco-2023

Following the 2023 ASCO Annual Meeting, Tanios S. Bekaii-Saab, MD, discusses recent data updates and provides clinical insights on the evolving treatment landscape for metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, an expert on colorectal cancer

EP. 1: Overview of Metastatic Colorectal Cancer: Presentation and Molecular Testing

July 14th 2023

Tanios S. Bekaii-Saab, MD, gives an overview of the presentation trends and molecular testing practices for metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, an expert on colorectal cancer

EP. 2: HER2 as a Biomarker in Metastatic Colorectal Cancer

July 14th 2023

An expert on colorectal cancer discusses the relationship between HER2 status and treatment selection and response.

Tanios S. Bekaii-Saab, MD, an expert on colorectal cancer

EP. 3: Evolving Treatment Landscape in Metastatic Colorectal Cancer

July 21st 2023

Tanios S. Bekaii-Saab, MD, discusses recent clinical trials and provides insights on the evolving metastatic colorectal cancer treatment landscape.

Tanios S. Bekaii-Saab, MD, an expert on colorectal cancer

EP. 4: DESTINY-CRC02: Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal Cancer

July 21st 2023

An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, an expert on colorectal cancer

EP. 5: Future Perspectives on HER2+ Metastatic Colorectal Cancer

July 28th 2023

Tanios S. Bekaii-Saab, MD, offers closing thoughts on the unmet needs and future of HER2+ metastatic colorectal cancer treatment.